Literature DB >> 11897050

A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors.

J Fraser Glickman1, Xiang Wu, Robert Mercuri, Chantal Illy, Benjamin R Bowen, Yang He, Matthew Sills.   

Abstract

New developments in detection technologies are providing a variety of biomolecular screening strategies from which to choose. Consequently, we performed a detailed analysis of both separation-based and non-separation-based formats for screening nuclear receptor ligands. In this study, time-resolved fluorescence resonance energy transfer (TR-FRET), ALPHAScreen, and time-resolved fluorescence (TRF) assays were optimized and compared with respect to sensitivity, reproducibility, and miniaturization capability. The results showed that the ALPHAScreen system had the best sensitivity and dynamic range. The TRF assay was more time consuming because of the number of wash steps necessary. The TR-FRET assay had less interwell variation, most likely because of ratiometric measurement. Both the ALPHAScreen and the TR-FRET assays were miniaturized to 8-microl volumes. Of the photomultiplier tube-based readers, the ALPHAScreen reader (ALPHAQuest) presented the advantage of faster reading times through simultaneous reading with four photomultiplier tubes.

Mesh:

Substances:

Year:  2002        PMID: 11897050     DOI: 10.1177/108705710200700102

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  33 in total

Review 1.  Design and implementation of high throughput screening assays.

Authors:  Ricardo Macarrón; Robert P Hertzberg
Journal:  Mol Biotechnol       Date:  2011-03       Impact factor: 2.695

2.  Post-translational modifications differentially affect IgG1 conformation and receptor binding.

Authors:  Damian Houde; Yucai Peng; Steven A Berkowitz; John R Engen
Journal:  Mol Cell Proteomics       Date:  2010-01-26       Impact factor: 5.911

Review 3.  Drug discovery and development for rare genetic disorders.

Authors:  Wei Sun; Wei Zheng; Anton Simeonov
Journal:  Am J Med Genet A       Date:  2017-07-21       Impact factor: 2.802

4.  In pursuit of synthetic modulators for the orphan retina-specific nuclear receptor NR2E3.

Authors:  Qiong Qin; Anna Knapinska; Nicoleta Dobri; Franck Madoux; Peter Chase; Peter Hodder; Konstantin Petrukhin
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-25       Impact factor: 2.671

5.  The use of AlphaScreen technology in HTS: current status.

Authors:  Richard M Eglen; Terry Reisine; Philippe Roby; Nathalie Rouleau; Chantal Illy; Roger Bossé; Martina Bielefeld
Journal:  Curr Chem Genomics       Date:  2008-02-25

6.  Cellular Ser/Thr-kinase assays using generic peptide substrates.

Authors:  Deanna G Adams; Yu Wang; Puiying A Mak; Jason Chyba; Orzala Shalizi; Jason Matzen; Paul Anderson; Tim R Smith; Michael Garcia; Genevieve L Welch; Emmanuel J Claret; Michel Fink; Anthony P Orth; Jeremy S Caldwell; Achim Brinker
Journal:  Curr Chem Genomics       Date:  2008-05-23

7.  A live zebrafish-based screening system for human nuclear receptor ligand and cofactor discovery.

Authors:  Jens Tiefenbach; Pamela R Moll; Meryl R Nelson; Chun Hu; Lilia Baev; Thomas Kislinger; Henry M Krause
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

8.  A novel high throughput 1536-well Notch1 γ -secretase AlphaLISA assay.

Authors:  De-Ming Chau; David Shum; Constantin Radu; Bhavneet Bhinder; David Gin; M Lane Gilchrist; Hakim Djaballah; Yue-Ming Li
Journal:  Comb Chem High Throughput Screen       Date:  2013-07       Impact factor: 1.339

9.  Development of a high-throughput screening assay for inhibitors of small ubiquitin-like modifier proteases.

Authors:  Wei Yang; Liangli Wang; Wulf Paschen
Journal:  J Biomol Screen       Date:  2013-03-07

10.  Ligand-binding domain of farnesoid X receptor (FXR) had the highest sensitivity and activity among FXR variants in a fluorescence-based assay.

Authors:  Kyung-Hyun Cho; Ji-Young Park; Jang-Il Han; Tae-Sook Jeong
Journal:  Lipids       Date:  2003-11       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.